News

GlobalData on MSN2mon
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
pharmaphorum2mon
FDA clears new antibiotic for superbug infections
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...
AbbVie Stock (ABBV) Up 8% on the Week as Company Soars Past Q1 Expectations
AbbVie (ABBV) delivered impressive financial results for the first quarter of 2025. Investors responded enthusiastically, ...
Hosted on MSN1y
EC approves Pfizer’s EMBLAVEO for multidrug-resistant infections
The European Commission (EC) has granted marketing authorisation for Pfizer’s EMBLAVEO (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options ...